# PP-0202 — Sentinel Lymph Node
## QA Report

# 1. QA Overview

| Criterion | Result |
|---|---|
| PP identity verified | PASS |
| Approved scope respected | PASS |
| Gold four-artifact structure | PASS |
| Source-first workflow | PASS |
| Absolute Gold-depth rule | PASS |
| Evidence traceability | PASS |
| Clinical safety | PASS |
| Patient-facing depth | PASS |
| Knowledge Graph | PASS |
| Boundary ownership | PASS |
| Evidence-gap handling | PASS |
| Versioning | PASS |

---

# Layer 1 — Content QA

## 1.1 Scope respected

**PASS**

The package focuses on the sentinel lymph-node concept in gastric cancer.

It does not become a general lymphadenectomy package.

---

## 1.2 Atomicity

**PASS**

The package answers one clinical educational question:

> What is a sentinel lymph node in gastric cancer, why might it be considered, how is it different from D1/D2, and what limitations matter?

---

## 1.3 Completeness

**PASS**

The CKO covers:

- definition;
- rationale;
- regional nodal context;
- D1/D2 distinction;
- early gastric cancer context;
- false-negative risk;
- result interpretation;
- patient questions;
- evidence limitations;
- Knowledge Graph;
- boundaries.

---

## 1.4 Internal consistency

**PASS**

The package consistently distinguishes:

- sentinel-node strategy;
- D1;
- D2;
- pathology;
- individualized treatment.

---

## 1.5 Evidence-gap completeness

**PASS**

The package does not hide the central limitation:

> the current 18 core PDFs do not provide enough dedicated gastric sentinel-node evidence for numerical accuracy, technical protocols, or universal indications.

---

# Layer 2 — Clinical QA

## 2.1 Regional lymph-node framework

**PASS**

The package is consistent with the supplied NCCN framework that gastric resection includes regional lymph-node management and that D1/D2 represent different anatomical extents.

---

## 2.2 D1/D2 distinction

**PASS**

D1/D2 are presented as field lymphadenectomy.

Sentinel-node assessment is presented as a different selective strategy.

---

## 2.3 False-negative safety

**PASS**

False-negative assessment is explicitly identified as the central safety concern.

---

## 2.4 Negative sentinel-node interpretation

**PASS**

The package does not state that a negative sentinel node proves absence of all regional nodal disease.

---

## 2.5 Cross-cancer evidence transfer

**PASS**

Sentinel-node evidence from melanoma, breast, vulvar, penile, or other cancers is not used to establish gastric-cancer practice.

---

## 2.6 Unsupported numerical claims

**PASS**

No unsupported:

- sensitivity;
- specificity;
- detection rate;
- false-negative rate;
- tumor-size cutoff;
- T-stage cutoff;
- center-volume threshold

is introduced.

---

## 2.7 Operative safety

**PASS**

No procedural instructions are provided.

The package does not instruct the reader how to perform lymphatic mapping, inject tracers, identify nodes, or conduct surgery.

---

## 2.8 Treatment safety

**PASS**

No individualized recommendation is made regarding:

- sentinel-node biopsy;
- D1;
- D2;
- gastrectomy;
- chemotherapy;
- immunotherapy;
- targeted therapy.

---

## 2.9 Guideline-status calibration

**PASS**

The package does not claim that sentinel-node assessment is universal gastric-cancer standard of care based on the current source set.

---

## 2.10 Early gastric cancer

**PASS**

Early gastric cancer is presented as an important clinical context, not as a universal sentinel-node indication.

---

# Layer 3 — Educational QA

## 3.1 Plain language

**PASS**

Medical terms are explained at first use.

---

## 3.2 Patient-centeredness

**PASS**

The package contains direct patient explanations and question-based runtime patterns.

---

## 3.3 Logical learning progression

**PASS**

The sequence is:

1. What is a sentinel node?
2. Why do nodes matter?
3. How does it differ from D1/D2?
4. Why is early disease relevant?
5. Why might selective assessment be attractive?
6. What is the key safety problem?
7. What do positive/negative findings mean?
8. What remains uncertain?
9. What should the patient ask?

---

## 3.4 Misconception handling

**PASS**

Dedicated misconceptions address:

- sentinel node = no lymph-node surgery;
- negative = no cancer anywhere;
- sentinel = D1;
- sentinel = small D2;
- positive = automatic treatment;
- other-cancer evidence = gastric evidence;
- early cancer = no nodal risk;
- sentinel node = closest node;
- one node is always enough;
- sentinel node = automatically safer.

---

## 3.5 Uncertainty communication

**PASS**

The package explicitly separates:

- established;
- conceptual/context-dependent;
- unsupported by current source set.

---

## 3.6 Practical patient usefulness

**PASS**

Patients are given questions about:

- evidence;
- accuracy;
- false-negative risk;
- institutional experience;
- whether the approach is validated;
- relationship to D1/D2;
- pathology;
- next-step decision-making.

---

# Layer 4 — Governance QA

## 4.1 CKO completed

**PASS**

`01_CKO.md` is complete.

---

## 4.2 Knowledge Passport completed

**PASS**

`02_KNOWLEDGE_PASSPORT.md` is complete.

---

## 4.3 Primary Evidence Package completed

**PASS**

`03_PRIMARY_EVIDENCE_PACKAGE.md` is complete.

---

## 4.4 QA Report completed

**PASS**

This artifact is complete.

---

## 4.5 Gold specification followed

**PASS**

The four-artifact structure follows the locked Gold specification.

---

## 4.6 Approved Decision Batch respected

**PASS**

The package implements the approved PP-0202 scope.

No scope reopening occurred.

---

## 4.7 Source-first rule

**PASS**

The project Source Files were searched before production.

Relevant gastric sources were identified.

The dedicated gastric sentinel-node evidence gap was explicitly preserved.

---

## 4.8 Gold depth

**PASS**

The package was produced at full Gold depth and was not intentionally compacted.

---

## 4.9 Boundary

**PASS**

Boundary uses:

- Core;
- Supporting;
- Explicitly Excluded;
- Delegated-to PP.

It is ownership-oriented and non-duplicative.

---

## 4.10 Knowledge Graph

**PASS**

Prerequisite, related, and downstream relationships are defined.

---

## 4.11 Versioning

**PASS**

Semantic version `1.0.0` is used consistently.

---

## 4.12 Repository readiness

**PASS**

The package contains exactly the four required Markdown artifacts and is packaged as one ZIP.

---

# Evidence Traceability QA

| Area | Result | QA finding |
|---|---|---|
| Gastric lymph-node framework | PASS | Anchored to NCCN/NCI/ACS gastric sources |
| D1/D2 definitions | PASS | NCCN primary |
| Early gastric cancer context | PASS | NCCN/NCI |
| Surgical expertise | PASS | NCCN/ACS |
| Sentinel-node technical protocol | NOT CLAIMED | Source gap preserved |
| Sentinel-node accuracy | NOT CLAIMED | Source gap preserved |
| False-negative percentage | NOT CLAIMED | Source gap preserved |
| Universal eligibility | NOT CLAIMED | Source gap preserved |
| Cross-cancer extrapolation | PASS | Explicitly prohibited |
| Individualized treatment | PASS | Explicitly excluded |

---

# Boundary QA

## PP-0199

**PASS**

General lymphadenectomy remains upstream.

---

## PP-0200

**PASS**

D1-specific anatomy remains separate.

---

## PP-0201

**PASS**

D2-specific anatomy and evidence remain separate.

---

## PP-0193

**PASS**

Endoscopic-resection pathway remains separate.

---

## PP-0194

**PASS**

EMR remains separate.

---

## PP-0195

**PASS**

ESD remains separate.

---

## PP-0196–0198

**PASS**

Gastrectomy principles and gastrectomy-type packages remain separate.

---

## PP-0203 onward

**PASS**

Systemic-treatment packages remain downstream.

---

# Clinical Safety Review

| Item | Result |
|---|---|
| No individualized surgical recommendation | PASS |
| No individualized D1/D2 recommendation | PASS |
| No unsupported sentinel-node indication | PASS |
| No unsupported numerical performance claims | PASS |
| No operative instructions | PASS |
| No cross-cancer evidence transfer | PASS |
| Negative-result uncertainty preserved | PASS |
| False-negative risk highlighted | PASS |
| Evidence gap disclosed | PASS |
| No treatment prescription | PASS |

---

# Gold Depth Integrity Review

## CKO

**PASS**

Full clinical knowledge blocks, patient explanation, misconceptions, key messages, evidence calibration, and Knowledge Graph are present.

## Knowledge Passport

**PASS**

Identity, classification, runtime usage, retrieval safety, evidence classification, governance, Knowledge Graph, and boundary metadata are present.

## Evidence Package

**PASS**

Clinical question, educational intent, source hierarchy, evidence matrix, evidence gaps, traceability, claim calibration, boundary verification, and future update triggers are present.

## QA Report

**PASS**

Four-layer QA is substantive and includes content, clinical, educational, governance, traceability, safety, boundary, and Gold-depth checks.

---

# Final QA Decision

## PASS

PP-0202 satisfies the approved Decision Batch and the locked Gold Population Package production standard.

The package deliberately preserves the project's Source-First rule:

> **Where the current Source Materials do not support a gastric-specific sentinel-node claim, the package does not invent one.**

The two principal safety statements are:

> **Sentinel-node assessment is a selective regional nodal strategy, not another numerical level of lymphadenectomy.**

and

> **A negative sentinel-node result cannot automatically be treated as proof that all regional lymph nodes are free of cancer unless the strategy is validated for that clinical setting.**

---

# Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**
